CTIBIOTECH

CTIBIOTECH™ specializes in the production of human tissues using 3D bioprinting and additive manufacturing for biomedical, pharmaceutical, and dermato-cosmetic research and development. CTIBIOTECH™ fosters innovative solutions for preclinical evaluation (efficacy and safety testing) of active ingredients, dermo-cosmetic products, therapeutic candidates, cell therapies, aesthetic devices, and medical devices. We industrialize the production of bioassays from biopsies collected with patient consent for medical, pharmaceutical and dermatocosmetics innovation.

CTIBIOTECH™ has developed a biobank with capacity of 50 000 clinical samples in collaboration French and European hospitals from living donors that provided ethical informed consent. We mass-produce human skin models, tumor models containing the patient’s immune system, or human liver models enabling high value-added biomedical innovation. These unique industrial processes are based on 3D bioprinting, an additive manufacturing method that enables reproducible and precise production of patient-specific human tissues. We evaluate, for example, the response to anti-cancer drugs, the efficacy of a cosmetic product, treatments for burn victims or the safety of vaccines.

CTIBIOTECH™ is looking for academic, industrial, financial and commercial partners to accelerate its technological developments in human tissue bioproduction (preclinical and clinical), with additive manufacturing, lab-on-chip, organ-on-chip in Japan and worldwide.